Kodiak Sciences (STU:K27) OCF Margin %: 0.00% (As of Mar. 2026)


STU:K27 Kodiak Sciences Inc STU:K27
27 GF Score
Price €31.62
! 3 Warning Signs
View Full Analysis

What is Kodiak Sciences OCF Margin %?

Kodiak Sciences STU:K27 -2.92% 27 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:K27 with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Kodiak Sciences ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Kodiak Sciences's Cash Flow from Operations for the three months ended in Mar. 2026 was €-34.61 Mil. Kodiak Sciences's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Kodiak Sciences's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Kodiak Sciences's current OCF Yield % is -6.32%.

The historical rank and industry rank for Kodiak Sciences's OCF Margin % or its related term are showing as below:


STU:K27's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Kodiak Sciences OCF Margin % Related Terms

Kodiak Sciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Kodiak Sciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences OCF Margin % Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kodiak Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:K27
27GF Score
Kodiak Sciences Inc STU:K27
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Kodiak Sciences's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-116.151/0
= %

Kodiak Sciences's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-34.608/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Kodiak Sciences (STU:K27) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kodiak Sciences and its competitors. According to the industry distribution chart, Kodiak Sciences ranks #999999 out of 960 companies in the Biotechnology industry.
Is Kodiak Sciences' OCF Margin % too high?
Kodiak Sciences' current OCF Margin % is 0.00%. Based on the distribution chart, Kodiak Sciences ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' OCF Margin % compare to RARE and NKTR?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #999999 out of 960 companies for OCF Margin %. This places Kodiak Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (STU:K27) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Kodiak Sciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kodiak Sciences (STU:K27), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges KOD:USA
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score

Get the complete analysis for STU:K27

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.62
Price